Clinical trial · Observational
Confocal Microscopy Dual Band in the Management of Bladder Cancer
Study of the Contribution of Confocal Microscopy Dual Band in the Management of Bladder Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Bladder cancer is one of the most common cancer worldwide and the second most frequent urological cancer. The photodynamic diagnosis technique (PDD) currently used (Hexvix®) has improved tumor detection but with a high false positive rate. Indeed, the main limitation of the PDD is its lack of specificity, ranging from 35 to 66%. The association of this technique with new technologies such as the Cellvizio Dual Band featuring simultaneous dual wavelength illumination and detection, could improve the identification of tumoral lesions. The objective of this study is to demonstrate the efficacy of Cellvizio dual band technique for the diagnosis of tumors bladders.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Urinary Bladder Neoplasm | Bladder Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cellvizio dual band | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Bladder tumor resection
- interventionNames
- Device: Cellvizio dual band
Primary outcomes (1)
- measure
- Determination of the nucleo-cytoplasmic ratio of cells
- timeFrame
- at inclusion
- description
- In order to perform comparison between benign versus malignant cytology, significant differences between cytoplasmic areas and nuclear areas will be determine to stablish a value of nucleo-cytoplasmic ratio
Secondary outcomes (1)
- measure
- Number of neoplastic lesions identified by Cellvizio compared to number of lesions identified by pathology
- timeFrame
- through the study completion, an average of 6 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients having 18 years old or more * Patients with a bladder carcinoma and with indication of tumor resection under Hexvix procedure. * Patients giving consent to participate in the study Exclusion Criteria: -No consent to participate in the study
References
Publications (0)
Data not yet available